Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma

Kohei Shitara; Yung-Jue Bang; Satoru Iwasa; Naotoshi Sugimoto; Min-Hee Ryu; Daisuke Sakai; Hyun Cheol Chung; Yasushi Omuro; Hisato Kawakami; Hiroshi Yabusaki; Yasuhiro Sakamoto; Tomohiro Nishina; Koichiro Inaki; Yusuke Kuwahara; Fumitaka Suto; Masahiro Sugihara; Kaku Saito; Akihito Kojima; Kensei Yamaguchi

doi:10.1200/JCO.2022.40.4_suppl.322

YUHSpace

BROWSE

0 152

Cited 0 times in

Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma

Authors: Kohei Shitara ; Yung-Jue Bang ; Satoru Iwasa ; Naotoshi Sugimoto ; Min-Hee Ryu ; Daisuke Sakai ; Hyun Cheol Chung ; Yasushi Omuro ; Hisato Kawakami ; Hiroshi Yabusaki ; Yasuhiro Sakamoto ; Tomohiro Nishina ; Koichiro Inaki ; Yusuke Kuwahara ; Fumitaka Suto ; Masahiro Sugihara ; Kaku Saito ; Akihito Kojima ; Kensei Yamaguchi